Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

1598405

USP

Ranitidine hydrochloride

United States Pharmacopeia (USP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C13H22N4O3S · HCl
Numéro CAS:
Poids moléculaire :
350.86
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ranitidine

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Cl[H].CN\C(NCCSCc1ccc(CN(C)C)o1)=C\[N+]([O-])=O

InChI

1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H/b13-9-;

Clé InChI

GGWBHVILAJZWKJ-CHHCPSLASA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ranitidine hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Ranitidine Injection
  • Ranitidine Tablets
  • Ranitidine in Sodium Chloride Injection
  • Ranitidine Oral Solution

Actions biochimiques/physiologiques

H2 histamine receptor antagonist; anti-ulcer agent.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazardExclamation mark

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Travis Nemkov et al.
JCI insight, 6(3) (2020-12-23)
Computational models based on recent maps of the RBC proteome suggest that mature erythrocytes may harbor targets for common drugs. This prediction is relevant to RBC storage in the blood bank, in which the impact of small molecule drugs or
Natalia Alonso et al.
The Biochemical journal, 459(1), 117-126 (2014-01-15)
7TMRs (seven-transmembrane receptors) exist as conformational collections in which different conformations would lead to differential downstream behaviours such as receptor phosphorylation, G-protein activation and receptor internalization. In this context, a ligand may cause differential activation of some, but not all
M B Evans et al.
Journal of pharmaceutical and biomedical analysis, 7(1), 1-22 (1989-01-01)
The selection, development, definition and validation of selective stability-indicating procedures for high-performance liquid chromatographic and thin-layer chromatographic analyses of ranitidine hydrochloride are described. The procedures used in conjunction can be applied to the quality assurance and stability assessments of both
[The development of hemorrhagic vasculitis (Schönlein-Henoch disease) in a patient with a chronic stomach ulcer against a background of Sostril (ranitidine hydrochloride) therapy].
E N Glazunov et al.
Vestnik khirurgii imeni I. I. Grekova, 152(1-2), 102-103 (1994-01-01)
Question 1: does the use of ranitidine increase the risk of NEC in preterm infants?
Manigandan Chandrasekaran et al.
Archives of disease in childhood, 99(4), 390-392 (2014-03-15)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique